Use of medication during the last 12 months in the random sample#

ECRHS IECRHS IIECRHS IIIChange in prevalence
Inhaled SABAs3. (2.0–3.4)
Inhaled LABAs1.24.23.0 (2.4–3.6)
ICSs1. (3.5–4.9)
ICS+LABA0.93.82.9 (2.4–3.5)
Inhaled anticholinergics0. (0.07–5.1)
Theophylline0.70.20.1−0.6 (−0.9– −0.4)
Oral β2-agonists0.40.30−0.4+
LTRAs0.20.60.4 (0.2–0.7)
OCSs0. (0.1–0.8)
Any medication for asthma5. (3.9–5.6)

Data are presented as %, and change between European Community Respiratory Health Survey (ECRHS) I and III in % (95% CI), or in case of absence of information from ECRHS I, change between ECRHS II and ECRHS III in % (95% CI). SABA: short-acting β2-agonist; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid; LTRA: leukotriene receptor antagonist; OCS: oral corticosteroid. #: n=4617; : as a single inhaler or in combination; +: not possible to calculate 95% confidence interval.